The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers with high unmet medical need. The program aims to encourage innovation and translation of ideas...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or high response rates, they are not risk-free. Reports of immune-related adverse events (therapy-dependent toxicities caused...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence, asked the audience as he opened the “PD-1 Pandemonium: FDA Speaks with Industry on the Past, Present, and Future of PD-1 Drugs” regulatory science and policy session at the American Association for Cancer Research (AACR) Annual Meeting 2019 on Monday, April 1.
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including melanoma, lung cancer, head and neck cancer, bladder cancer, cervical cancer, liver cancer, stomach cancer, breast cancer, lymphoma, and to treat patients with any type of solid tumor that is microsatellite instability–high or mismatch repair–deficient.
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more than 15 percent of new cancer cases were attributed to carcinogenic infection, and the top...
Cancer immunotherapy research has exploded in recent years. This treatment utilizes a patient’s own immune system to recognize and attack cancer cells. While many successful immunotherapeutic regimens have relied on checkpoint inhibition, other immunotherapeutic approaches, such as adoptive cellular therapies (ACT), the use of bispecific antibodies, and targeting components of the tumor microenvironment, are showing promise in a variety of cancer types.
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric antigen receptor (CAR) T-cell therapies for patients with advanced solid tumors.
Recent advances in cancer research has led to enormous progress against many cancer types. From 1991 to 2015, we witnessed a 26 percent reduction in the U.S. cancer death rate, representing over 2 million...
The AACR Annual Meeting 2019 features the theme “Integrative Cancer Science • Global Impact • Individualized Patient Care.” That theme provided the structure for Monday’s plenary session, when cancer researchers representing three continents, four cancer types,...
Cancer prevention refers to measures that people can take to reduce their risk of developing cancer. These measures can include lifestyle changes, like eliminating tobacco use, maintaining a healthy weight, staying active, and limiting...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More